The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective in preventing HIV acquisition.
The National Department of Health is introducing a new drug, Dolutegravir (DTG), in combination with Tenofovir (TDF) and Lamivudine (3TC). The combination of TDF/3TC/DTG is known as TLD. The objectives of this training are to:
UNAIDS study shows that the impact on production and logistics caused by COVID-19 could have a significant effect on antiretroviral therapy supply worldwide, but steps taken now could lessen the damage done
Darunavir/ritonavir administered with rifampicin causes hepatotoxicities in people living with HIV, according to results of a study led by researchers at the department of medicine, the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa) and the Desm